Novo Nordisk Dodges PTAB Review On Lucrative Ozempic IP
The Patent Trial and Appeal Board will not review whether a pair of Novo Nordisk patents covering its blockbuster diabetes and weight-loss drug Ozempic should be invalidated. ...To view the full article, register now.
Already a subscriber? Click here to view full article